• Alhadrami, H.A., Sayed, A.M., Sharif, A.M., Azhar, E.I., Rateb, M.E., 2021. Olive-derived triterpenes suppress SARS-COV-2 main protease: A promising scaffold for future therapeutics. Molecules 26, 2654.

  • Chaves, O.A., Lima, C.R., Fintelman-Rodrigues, N., Sacramento, C.Q., de Freitas, C.S., Vazquez, L., Temerozo, J.R., Rocha, M.E.N., Dias, S.S.G., Carels, N., et al., 2022. Agathisflavone, a natural biflavonoid that inhibits SARS-CoV-2 replication by targeting its proteases. Int. J. Biol. Macromol. 222, 1015-1026.

  • Chen, Q., Rahman, K., Wang, S.J., Zhou, S., Zhang, H., 2020. Scutellaria barbata: A review on chemical constituents, pharmacological cctivities and clinical applications. Curr. Pharm. Des. 26, 160-175.

  • Chen, Z., Cui, Q., Ran, Y., Achi, J.G., Chen, Z., Rong, L., Du, R., 2024. A BSL-2 compliant mouse model of SARS-CoV-2 infection for efficient and convenient antiviral evaluation. J. Virol. 98, e0050424.

  • Cheng, F.J., Ho, C.Y., Li, T.S., Chen, Y., Yeh, Y.L., Wei, Y.L., Huynh, T.K., Chen, B.R., Ko, H.Y., Hsueh, C.S., et al., 2023. Umbelliferone and eriodictyol suppress the cellular entry of SARS-CoV-2. Cell Biosci. 13, 118.

  • De Stefano, L., Bobbio-Pallavicini, F., Manzo, A., Montecucco, C., Bugatti, S., 2020. A "window of therapeutic opportunity" for anti-cytokine therapy in patients with coronavirus disease 2019. Front. Immunol. 11, 572635.

  • Del Valle, D.M., Kim-Schulze, S., Huang, H.H., Beckmann, N.D., Nirenberg, S., Wang, B., Lavin, Y., Swartz, T.H., Madduri, D., Stock, A., et al., 2020. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat. Med. 26, 1636-1643.

  • Du, R., Cooper, L., Chen, Z., Lee, H., Rong, L., Cui, Q., 2021. Discovery of chebulagic acid and punicalagin as novel allosteric inhibitors of SARS-CoV-2 3CLpro. Antiviral Res. 190, 105075.

  • Gaisina, I., Li, P., Du, R., Cui, Q., Dong, M., Zhang, C., Manicassamy, B., Caffrey, M., Moore, T., Cooper, L., Rong, L., 2024. An orally active entry inhibitor of influenza A viruses protects mice and synergizes with oseltamivir and baloxavir marboxil. Sci. Adv. 10, eadk9004.

  • Huang, S.T., Chen, Y., Chang, W.C., Chen, H.F., Lai, H.C., Lin, Y.C., Wang, W.J., Wang, Y.C., Yang, C.S., Wang, S.C., et al., 2021. Scutellaria barbata D. Don inhibits the main proteases (Mpro and TMPRSS2) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Viruses 13, 826.

  • Jamilloux, Y., Henry, T., Belot, A., Viel, S., Fauter, M., El Jammal, T., Walzer, T., Francois, B., Seve, P., 2020. Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions. Autoimmun. Rev. 19, 102567.

  • Lee, Y.G., Kang, K.W., Hong, W., Kim, Y.H., Oh, J.T., Park, D.W., Ko, M., Bai, Y.F., Seo, Y.J., Lee, S.M., et al., 2021. Potent antiviral activity of Agrimonia pilosa, Galla rhois, and their components against SARS-CoV-2. Bioorg. Med. Chem. 45, 116329.

  • Li, P., Chen, Z., Cui, Q., Du, R., 2021. Discovery of SARS-CoV-2 3CL protease inhibitors from pre-fractionated traditional Chinese medicine. China Journal of Traditional Chinese Medicine and Pharmacy 36, 6154-6157.

  • Li, S., 2024. Studies on chemical constituents and anti-inflammatory activity of scutellaria barbata. Wuyi University.

  • Li, Y., Wu, Y., Li, S., Li, Y., Zhang, X., Shou, Z., Gu, S., Zhou, C., Xu, D., Zhao, K., et al., 2022. Identification of phytochemicals in Qingfei Paidu decoction for the treatment of coronavirus disease 2019 by targeting the virus-host interactome. Biomed. Pharmacother. 156, 113946.

  • Liu, J., Meng, J., Li, R., Jiang, H., Fu, L., Xu, T., Zhu, G.Y., Zhang, W., Gao, J., Jiang, Z.H., et al., 2022. Integrated network pharmacology analysis, molecular docking, LC-MS analysis and bioassays revealed the potential active ingredients and underlying mechanism of Scutellariae radix for COVID-19. Front. Plant Sci. 13, 988655.

  • Liu, Y., Sa, K., Xu, W., Chen, Y., Liang, J., Zou, P., Chen, L., 2023. 1,7-Bis(4-hydroxyphenyl)-1,4,6-heptatrien-3-one inhibits SARS-CoV-2 by targeting the nucleocapsid protein. Acta Materia Medica 2, 270-280.

  • Mori, M., Quaglio, D., Calcaterra, A., Ghirga, F., Sorrentino, L., Cammarone, S., Fracella, M., D'Auria, A., Frasca, F., Criscuolo, E., et al., 2023. Natural flavonoid derivatives have pan-coronavirus antiviral activity. Microorganisms 11, 314.

  • Ru, J., Li, P., Wang, J., Zhou, W., Li, B., Huang, C., Li, P., Guo, Z., Tao, W., Yang, Y., et al., 2014. TCMSP: a database of systems pharmacology for drug discovery from herbal medicines. J. Cheminform. 6, 13.

  • Saravolatz, L.D., Depcinski, S., Sharma, M., 2023. Molnupiravir and nirmatrelvir-ritonavir: Oral coronavirus disease 2019 antiviral drugs. Clin. Infect Dis. 76, 165-171.

  • Shen, Z., Ratia, K., Cooper, L., Kong, D., Lee, H., Kwon, Y., Li, Y., Alqarni, S., Huang, F., Dubrovskyi, O., et al., 2022. Design of SARS-CoV-2 PLpro inhibitors for COVID-19 antiviral therapy leveraging binding cooperativity. J. Med. Chem. 65, 2940-2955.

  • Shi, N., Liu, B., Liang, N., Ma, Y., Ge, Y., Yi, H., Wo, H., Gu, H., Kuang, Y., Tang, S., et al., 2020. Association between early treatment with Qingfei Paidu decoction and favorable clinical outcomes in patients with COVID-19: A retrospective multicenter cohort study. Pharmacol. Res. 161, 105290.

  • Sjaarda, C.P., Lau, L., Simpson, J.T., Fattouh, R., Biondi, M.J., Maguire, F., Campigotto, A., Feng, Y., Tozer, K., Wong, H., et al., 2023. Prevalence of low-frequency, antiviral resistance variants in SARS-CoV-2 isolates in Ontario, Canada, 2020-2023. JAMA Netw. Open 6, e2324963.

  • Tan, B., Zhang, X., Ansari, A., Jadhav, P., Tan, H., Li, K., Chopra, A., Ford, A., Chi, X., Ruiz, F.X., et al., 2024. Design of a SARS-CoV-2 papain-like protease inhibitor with antiviral efficacy in a mouse model. Science 383, 1434-1440.

  • Wang, L., Chen, W., Li, M., Zhang, F., Chen, K., Chen, W., 2020. A review of the ethnopharmacology, phytochemistry, pharmacology, and quality control of Scutellaria barbata D. Don. J. Ethnopharmacol. 254, 112260.

  • Xie, Y., Yin, W., Zhang, Y., Shang, W., Wang, Z., Luan, X., Tian, G., Aisa, H.A., Xu, Y., Xiao, G., et al., 2021. Design and development of an oral remdesivir derivative VV116 against SARS-CoV-2. Cell Res. 31, 1212-1214.

  • Yisimayi, A., Song, W., Wang, J., Jian, F., Yu, Y., Chen, X., Xu, Y., Yang, S., Niu, X., Xiao, T., et al., 2024. Repeated Omicron exposures override ancestral SARS-CoV-2 immune imprinting. Nature 625, 148-156.

  • Zhang, C., Chen, G., Tang, G., Xu, X., Feng, Z., Lu, Y., Chan, Y.-T., Wu, J., Chen, Y., Xu, L., et al., 2023. Multi-component Chinese medicine formulas for drug discovery: State of the art and future perspectives. Acta Materia Medica 2, 106-125.

  • Zhang, L., Lin, D., Sun, X., Curth, U., Drosten, C., Sauerhering, L., Becker, S., Rox, K., Hilgenfeld, R., 2020. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors. Science 368, 409-412.

  • Zhang, L., Zheng, X., Bai, X., Wang, Q., Chen, B., Wang, H., Lu, J., Hu, S., Zhang, X., Zhang, H., et al., 2021. Association between use of Qingfei Paidu Tang and mortality in hospitalized patients with COVID-19: A national retrospective registry study. Phytomedicine. 85, 153531.

  • Zhao, J., Ma, Q., Zhang, B., Guo, P., Wang, Z., Liu, Y., Meng, M., Liu, A., Yang, Z., Du, G., 2021. Exploration of SARS-CoV-2 3CLpro inhibitors by virtual screening methods, FRET Detection, and CPE Assay. J. Chem. Inf. Model 61, 5763-5773.

  • Zuckerman, N.S., Bucris, E., Keidar-Friedman, D., Amsalem, M., Brosh-Nissimov, T., 2024. Nirmatrelvir resistance-de novo E166V/L50V mutations in an immunocompromised patient treated with prolonged nirmatrelvir/ritonavir monotherapy leading to clinical and virological treatment failure-a case report. Clin. Infect. Dis. 78, 352-355.